title: Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?
abstract: In the past year, there has been increasing attention towards understanding the clinical relevance of minimal residual disease (MRD) assessment. The monitoring of MRD levels at various stages of therapy has considerable potential to impact the guidance of treatment for AML patients and improve outcomes. Thus, efforts have increased to address important concerns regarding MRD measurements. These concerns include: (1) what should be monitored; (2) what methodologies should be used; (3) whether such methodologies are standardized across laboratories; (4) how prognostic levels are defined; (5) when MRD should be monitored; and (6) what treatment options are available for MRD positive patients. In this review, we will discuss the methodologies available for MRD and the studies available to date aiming to address the concerns around the use of MRD measurements for AML patients.
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
authors.forename: Karen-Sue B
authors.initials: KS
authors.lastname: Carlson
authors.forename: Monica L
authors.initials: ML
authors.lastname: Guzman
mesh_terms: D000328:Adult; D003657:Decision Making; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis*; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods
references.citation: Leukemia. 2006 Mar;20(3):451-7
references.pmid: 16424875
references.citation: Blood. 2003 Jul 1;102(1):43-52
references.pmid: 12623843
references.citation: Curr Opin Oncol. 2012 Nov;24(6):711-9
references.pmid: 23014187
references.citation: Blood. 1998 Oct 1;92(7):2322-33
references.pmid: 9746770
references.citation: Lancet Oncol. 2010 Jun;11(6):543-52
references.pmid: 20451454
references.citation: Expert Rev Hematol. 2009 Dec;2(6):663-72
references.pmid: 21082958
references.citation: Curr Opin Oncol. 2009 Nov;21(6):582-8
references.pmid: 19667983
references.citation: Am J Clin Pathol. 2009 Jan;131(1):16-26
references.pmid: 19095561
references.citation: Leukemia. 2000 Oct;14(10):1777-84
references.pmid: 11021753
references.citation: Leukemia. 2006 Oct;20(10):1783-9
references.pmid: 16838027
references.citation: Leukemia. 2007 Aug;21(8):1700-7
references.pmid: 17525725
references.citation: Blood. 2007 Oct 1;110(7):2659-66
references.pmid: 17609428
references.citation: Cytometry. 2000 Aug 15;42(4):247-53
references.pmid: 10934344
references.citation: J Clin Oncol. 2012 Dec 20;30(36):4515-23
references.pmid: 22987078
references.citation: Leukemia. 2012 Mar;26(3):381-9
references.pmid: 21886171
references.citation: Blood. 2000 Dec 1;96(12):3948-52
references.pmid: 11090082
references.citation: Blood. 2012 Jul 12;120(2):468-72
references.pmid: 22517895
references.citation: Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
references.pmid: 20368434
references.citation: Blood. 2012 Apr 12;119(15):3571-7
references.pmid: 22262762
references.citation: Blood. 2003 May 1;101(9):3398-406
references.pmid: 12506020
references.citation: Blood. 1993 Jun 1;81(11):3083-90
references.pmid: 8499643
references.citation: Sci Transl Med. 2012 Aug 29;4(149):149ra118
references.pmid: 22932223
references.citation: Br J Haematol. 2006 Oct;135(2):165-73
references.pmid: 16939487
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4747-53
references.pmid: 19720919
references.citation: Best Pract Res Clin Haematol. 2011 Dec;24(4):485-8
references.pmid: 22127310
references.citation: Nat Med. 1997 Jul;3(7):730-7
references.pmid: 9212098
references.citation: N Engl J Med. 2012 Mar 22;366(12):1079-89
references.pmid: 22417203
references.citation: Am J Hematol. 2007 Sep;82(9):826-30
references.pmid: 17506065
references.citation: J Clin Oncol. 2012 Oct 10;30(29):3625-32
references.pmid: 22965955
references.citation: Br J Haematol. 2006 Jul;134(1):54-7
references.pmid: 16803567
references.citation: Lancet. 2006 Nov 25;368(9550):1894-907
references.pmid: 17126723
references.citation: Blood. 2004 Nov 15;104(10):3078-85
references.pmid: 15284114
references.citation: Blood. 2001 Sep 15;98(6):1746-51
references.pmid: 11535507
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13
references.pmid: 17576927
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3724-9
references.pmid: 20625124
references.citation: Leukemia. 2012 Sep;26(9):1986-2010
references.pmid: 22948490
references.citation: Crit Rev Oncol Hematol. 2011 Dec;80(3):331-46
references.pmid: 21123080
references.citation: Clin Cancer Res. 2005 Sep 15;11(18):6520-7
references.pmid: 16166428
references.citation: J Clin Oncol. 2003 Dec 15;21(24):4642-9
references.pmid: 14673054
references.citation: Blood. 2002 Dec 15;100(13):4325-36
references.pmid: 12393746
references.citation: Blood. 1990 Jul 1;76(1):163-71
references.pmid: 1973061
references.citation: Ann Oncol. 1992 Feb;3(2):107-11
references.pmid: 1318741
references.citation: Blood. 2012 Oct 4;120(14):2826-35
references.pmid: 22875911
references.citation: Cell. 2009 Jul 23;138(2):286-99
references.pmid: 19632179
references.citation: Exp Hematol. 2009 Jan;37(1):135-42
references.pmid: 19100523
references.citation: Genes Chromosomes Cancer. 2012 Jul;51(7):689-95
references.pmid: 22454318